Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009
Mon, March 16, 2009
Sun, March 15, 2009
Fri, March 13, 2009
Thu, March 12, 2009
Wed, March 11, 2009
Tue, March 10, 2009
Mon, March 9, 2009
Fri, March 6, 2009
Thu, March 5, 2009
Wed, March 4, 2009
Tue, March 3, 2009
Mon, March 2, 2009
Fri, February 27, 2009
Thu, February 26, 2009
Wed, February 25, 2009
Tue, February 24, 2009
Mon, February 23, 2009
Sun, February 22, 2009
Fri, February 20, 2009
Thu, February 19, 2009
[ Thu, Feb 19th 2009 ] - Market Wire
Enzon Reports 2008 Results
Wed, February 18, 2009
Tue, February 17, 2009

Exelixis Announces March 4 Webcast of Its Fourth Quarter and Full Year 2008 Financial Results Conference Call


//health-fitness.news-articles.net/content/2009/ .. year-2008-financial-results-conference-call.html
Published in Health and Fitness on Wednesday, February 25th 2009 at 5:29 GMT, Last Modified on 2009-02-25 05:30:05 by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (Nasdaq:EXEL) will release its fourth quarter and full year 2008 financial results on Wednesday, March 4, 2009 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. ET/ 2:00 p.m. PT, in which Exelixis management will discuss the financial results and the company's financial outlook, and will provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at [ www.exelixis.com ].

An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on April 4, 2009. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888, and the passcode is 34143616.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at [ www.exelixis.com ].


Publication Contributing Sources

Similar Health and Fitness Publications